Literature DB >> 30324526

Engineering Inducible Knock-In Mice to Model Oncogenic Brain Tumor Mutations from Endogenous Loci.

Jon D Larson1, Suzanne J Baker2.   

Abstract

To maximize the physiological relevance of in vivo brain tumor mouse models designed to study the downstream effects of oncogenic mutations, it is important to express the mutated genes at appropriate levels, in relevant cell types, and in the proper developmental context. For recurrent mutations found in the heterozygous state in tumors, expression of the mutation from the endogenous locus is a more physiologically relevant recapitulation of the brain tumor genome. Here, we describe an approach to generate knock-in mice with an inducible mutation recombined into the endogenous locus. In these engineered mice, the mutated allele is designed for expression controlled by the endogenous promoter and regulatory elements after Cre recombinase-mediated deletion of a loxP-STOP-loxP cassette inserted upstream of the translational start site. To preserve the structure of the endogenous locus, mutations or additional elements may need to be inserted at a considerable distance from the loxP-STOP-loxP cassette. We used recombineering to build a construct with two selectable markers and multiple genetic alterations that can be introduced into the endogenous allele in cis with a single ES cell targeting.

Entities:  

Keywords:  Brain tumor; Cre recombinase; Knock-in; Mouse; Mutation; Neuro-oncology; Oncogene; Recombineering; Transgenic; loxP

Mesh:

Year:  2019        PMID: 30324526      PMCID: PMC6432641          DOI: 10.1007/978-1-4939-8805-1_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  14 in total

1.  Multiplexing RMCE: versatile extensions of the Flp-recombinase-mediated cassette-exchange technology.

Authors:  Soeren Turan; Johannes Kuehle; Axel Schambach; Christopher Baum; Juergen Bode
Journal:  J Mol Biol       Date:  2010-07-19       Impact factor: 5.469

2.  One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering.

Authors:  Hui Yang; Haoyi Wang; Chikdu S Shivalila; Albert W Cheng; Linyu Shi; Rudolf Jaenisch
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

3.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

Review 4.  Review: insights gained from modelling high-grade glioma in the mouse.

Authors:  S L Rankin; G Zhu; S J Baker
Journal:  Neuropathol Appl Neurobiol       Date:  2012-06       Impact factor: 8.090

5.  A highly efficient recombineering-based method for generating conditional knockout mutations.

Authors:  Pentao Liu; Nancy A Jenkins; Neal G Copeland
Journal:  Genome Res       Date:  2003-03       Impact factor: 9.043

6.  Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.

Authors:  Lionel M L Chow; Raelene Endersby; Xiaoyan Zhu; Sherri Rankin; Chunxu Qu; Junyuan Zhang; Alberto Broniscer; David W Ellison; Suzanne J Baker
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

7.  De novo induction of genetically engineered brain tumors in mice using plasmid DNA.

Authors:  Stephen M Wiesner; Stacy A Decker; Jon D Larson; Katya Ericson; Colleen Forster; Jose L Gallardo; Chunmei Long; Zachary L Demorest; Edward A Zamora; Walter C Low; Karen SantaCruz; David A Largaespada; John R Ohlfest
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering.

Authors:  Haoyi Wang; Hui Yang; Chikdu S Shivalila; Meelad M Dawlaty; Albert W Cheng; Feng Zhang; Rudolf Jaenisch
Journal:  Cell       Date:  2013-05-02       Impact factor: 41.582

9.  Modeling Adult Gliomas Using RCAS/t-va Technology.

Authors:  Dolores Hambardzumyan; Nduka M Amankulor; Karim Y Helmy; Oren J Becher; Eric C Holland
Journal:  Transl Oncol       Date:  2009-05       Impact factor: 4.243

Review 10.  Applications of the CRISPR-Cas9 system in cancer biology.

Authors:  Francisco J Sánchez-Rivera; Tyler Jacks
Journal:  Nat Rev Cancer       Date:  2015-06-04       Impact factor: 60.716

View more
  3 in total

1.  A desirable transgenic strategy using GGTA1 endogenous promoter-mediated knock-in for xenotransplantation model.

Authors:  Nayoung Ko; Joohyun Shim; Hyoung-Joo Kim; Yongjin Lee; Jae-Kyung Park; Kyungmin Kwak; Jeong-Woong Lee; Dong-Il Jin; Hyunil Kim; Kimyung Choi
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

2.  Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression.

Authors:  Jon D Larson; Lawryn H Kasper; Barbara S Paugh; Hongjian Jin; Gang Wu; Chang-Hyuk Kwon; Yiping Fan; Timothy I Shaw; André B Silveira; Chunxu Qu; Raymond Xu; Xiaoyan Zhu; Junyuan Zhang; Helen R Russell; Jennifer L Peters; David Finkelstein; Beisi Xu; Tong Lin; Christopher L Tinkle; Zoltan Patay; Arzu Onar-Thomas; Stanley B Pounds; Peter J McKinnon; David W Ellison; Jinghui Zhang; Suzanne J Baker
Journal:  Cancer Cell       Date:  2018-12-27       Impact factor: 31.743

3.  Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.

Authors:  Ilango Balakrishnan; Etienne Danis; Angela Pierce; Krishna Madhavan; Dong Wang; Nathan Dahl; Bridget Sanford; Diane K Birks; Nate Davidson; Dennis S Metselaar; Michaël Hananja Meel; Rakeb Lemma; Andrew Donson; Trinka Vijmasi; Hiroaki Katagi; Ismail Sola; Susan Fosmire; Irina Alimova; Jenna Steiner; Ahmed Gilani; Esther Hulleman; Natalie J Serkova; Rintaro Hashizume; Cynthia Hawkins; Angel M Carcaboso; Nalin Gupta; Michelle Monje; Nada Jabado; Kenneth Jones; Nicholas Foreman; Adam Green; Rajeev Vibhakar; Sujatha Venkataraman
Journal:  Cell Rep       Date:  2020-10-20       Impact factor: 9.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.